Back to Journals » Research and Reports in Urology » Call For Papers

Research and Reports in Urology

ISSN: 2253-2447

The following Article Collection/ Thematic Series is currently open for submissions:

Therapeutic Advances in Urologic Malignancies

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Advancing Patient Safety Culture and Managing Healthcare Risks for Sustainable Healthcare", organized by Guest Advisor Werner T.W. de Riese in Research and Reports in Urology.

In recent years an evident paradigm shift has evolved across both local and systemic treatment choices for urologic malignancies. Regarding prostate cancer management, research has focused on a multitude of treatment options; whereas radical prostatectomy is well established for local disease, the role of pelvic lymph node dissection remains controversial, in particular in the context of metastatic disease on imaging. Adjuvant and early salvage radiotherapy offer distinct approaches, with recent studies indicating comparable outcomes. Systemic therapies continue to evolve as e.g., chemotherapy's role in radiation therapy is still an ongoing subject of clinical studies.

For locally advanced penile squamous cell carcinoma (PSCC), neoadjuvant chemotherapy and adjuvant therapy are actively explored as research is studying new drug regimens for first-line treatment options. While there are new and promising developments in understanding of cellular pathways and immune system targets for potential therapies, the results of limited trials are restricting their broad clinical application. Though the therapeutic achievements in systemic treatment of renal cell carcinoma currently rely on tyrosine kinase inhibitors with varying success, new certain immune checkpoint inhibitors are revealing very promising clinical results. Adjuvant therapy for urothelial carcinoma, in particular bladder cancer, has remained controversial in the literature, despite the proven effectiveness of neoadjuvant chemotherapy for muscle-invasive bladder cancer.

Practicing urologists and medical oncologists are often confronted with challenging clinical scenarios of urologic malignancies. Therefore, an update on recent advancements in the therapeutic outcome of difficult disease stages is appreciated as treating clinicians are ultimately driven to improve the chances of reducing disease burden, and thus improving patients’ survival. 

In this Collection, we are seeking original research articles as well as review papers. This Collection will include novel aspects of treatment options for urologic malignancies within the field of PSCC, prostate cancer, and bladder cancer. Among others, this collection will include primary discoveries as well as summaries of both adjuvant and neoadjuvant therapy, surgical treatment, use of checkpoint inhibitors, and hormonal therapy. The main goal and purpose of this Collection is bringing awareness about recent advancements for the different disease stages of these urologic malignancies.

All manuscripts submitted to this Article Collection will undergo desk assessment and peer-review as part of our standard editorial process. Please review the journal Aims and Scope and author submission instructions prior to submitting a manuscript.

The deadline for submissions is 3 May 2024.

Please submit your manuscript on our website, quoting the promo code XNJYG to indicate that your submission is for consideration in this Article Collection.

View all papers in this article collection

Call For Papers

To see where Research and Reports in Urology is indexed online view the Journal Metrics

What is the advantage to you of publishing in Research and Reports in Urology?

  • It is an open access journal which means that your paper is available to anyone in the world to download for free directly from the Dove website.
  • Unlike many traditional journals, your paper will not be rejected due to lack of space. We are an electronic journal and there are no limits on the number or size of the papers we can publish.
  • The time from submission to a decision being made on a paper can, in many journals, take some months and this is very frustrating for authors. Research and Reports in Urology has a quicker turnaround time than this. Generally peer review is complete within 3-4 weeks and the editor’s decision within 2-14 days of this. It is therefore very rare to have to wait more than 6 weeks for first editorial decision.
  • Many authors have found that our peer reviewer’s comments substantially add to their final papers.

To recover our editorial and production costs and continue to provide our content at no cost to readers we charge authors or their institution an article publishing charge.

PubMed Central
Research and Reports in Urology is indexed on PubMed Central (title abbreviation: Res Rep Urol). All published papers in this journal are submitted to PubMed for indexing straight away.

Become a Favored Author and receive real benefits
If you haven't already joined the Dove Press Favored Author Program I would encourage you to do so. Why? To receive real benefits like fast-tracking and a personal co-ordinator for your paper, as well as a discount on the publication processing fee.
Click here to go through to the Favored Author signup page.

Yours sincerely
Dr Panagiotis Vlachostergios
Research and Reports in Urology

Email: Editor-in-Chief